Term
| First generation antipsychotics |
|
Definition
| antagonism of dopamine (D-2) receptors |
|
|
Term
| positive symptoms primarily |
|
Definition
|
|
Term
| Thorazine (chlorpromazine) and Haldol (haloperidol) |
|
Definition
| most common first gen antipsychotics |
|
|
Term
| adverse motor effects of first gen antipsychotics |
|
Definition
| acute dystonia, pseudo-parkinsonism, akathisia, tardive dyskinesia |
|
|
Term
|
Definition
| onset 24-96 hours after first gen admin; involuntary tonic contraction of skeletal muscles; high risk for young MALES |
|
|
Term
|
Definition
| onset is 1-3 months after first gen use; rigidity, tremors, bradykinesia; high risk for OLDER patients |
|
|
Term
|
Definition
| onset is months to years after use of first gen; stereotypical involuntary movements ("sucking and lip smacking"); high risk of older FEMALES with history of mood disorders |
|
|
Term
|
Definition
| used for first gen antipsychotic adverse effect: acute dystonia and pseudo-parkinsonism |
|
|
Term
|
Definition
| onset is 3 months after use of first gen; subjective inner restlessness, fidgeting, pacing; high risk for ALL patients |
|
|
Term
| beta blockers and benzodiazepines |
|
Definition
| used for first gen antipsychotic adverse event: akathisia |
|
|
Term
|
Definition
| used for first gen antipsychotic adverse effect: tardive dyskinesia |
|
|
Term
| neuroleptic malignant disorder (NMS) |
|
Definition
| first gen antipsychotic adverse event of muscular rigidity, hyperthermia, change in mental status and autonomic dysfunction |
|
|
Term
| bromocriptine and/or dantrolene with hydration and cooling blankets |
|
Definition
| used for first gen antipsychotic adverse effect: neuroleptic malignant disorder |
|
|
Term
| other adverse effects of first gen antipsychotis |
|
Definition
| prolactin elevation, secondary negative symptoms, dermatologic, cardiac, hepatic, lowered seizure threshold, and hematologic |
|
|
Term
| second generation antipsychotic |
|
Definition
|
|
Term
| positive and negative symptoms |
|
Definition
| second generation antipsychotics (clozapine) |
|
|
Term
| adverse effects of second generation antipsychotics |
|
Definition
| QTC prolongation, increased mortality in dementia, Clozapine specifically: agranulocytosis, myocarditis, seizures) |
|
|
Term
| metabolic effects of antipsychotics |
|
Definition
| weight gain, diabetes risk and hyperlipidemia |
|
|
Term
| dosing considerations of antipsychotics |
|
Definition
| dose titration, divided doses to minimize motor, sedative and hypnotic effects |
|
|
Term
| IM or depo formulations for inadherent patients |
|
Definition
| haloperidol, fluphenazine, risperidone, paliperidone, olanzapine |
|
|
Term
|
Definition
| pharmacist/ prescriber coordinations to enter patient into manufacturers prescriber registry |
|
|
Term
| initial clozapine monitoring |
|
Definition
| WBC at 2500 and ANC at 2000 with repeated monitoring every week for 6 months |
|
|
Term
| clozapine monitoring for 6-12 month therapy |
|
Definition
| WBC at 3500 and ANC at 2000 with repeated monitoring Q 2 weeks |
|
|
Term
| clonzapine monitoring for therapy greater than 12 months |
|
Definition
| WBC at 3500 and ANC at 2000 with monitoring Q 4 weeks |
|
|
